Blue Matter Blog
November 20, 2023
For any company, a new product launch is a big deal. For an emerging biopharma company, the decision to launch a first product is a really big deal that sets in motion organizational transformation and a wide range of launch readiness activities. A biopharma company launching its first product will have significant investments over the …
August 28, 2023
If the leaders of an emerging biopharma company plan to commercialize their development-stage product(s), then they obviously must understand what capabilities, activities, and resources will be needed to commercialize successfully. But what about a company that has chosen a different strategic path? For example, does a company that plans to out-license a product to another …
November 8, 2019
The Blue Matter Breakfast Club is an ongoing series of quarterly two-hour breakfast forums, hosted by our Rare Diseases Team. These forums bring together leaders from companies that develop and commercialize rare disease therapies to discuss critical business issues. The third Breakfast Club meeting was on 5th November 2019 at Skylounge restaurant in Zug, Switzerland. …
January 28, 2019
Regardless of the product, launching a new biopharmaceutical drug is a time-consuming, expensive, and complex undertaking. It requires sound strategy, expert planning, and effective cross-functional coordination to get everything done right. The analogy is certainly not new but launch really is akin to conducting a symphony orchestra, ensuring that all members play their parts correctly, …
November 7, 2018
Part Two in a Six-Part Series on Oncology Product Commercialization In Part One, we mentioned that the launch frequency for oncology products has increased significantly over the last several years. While this trend is seen in other therapeutic areas across the industry, we believe the combination of factors driving this in oncology are somewhat unique …